All In Biotech

Drug Trial Radar · NCT05630833

A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)

A Phase III, Multicenter, Randomized, Active Reference, Double Blind, Double-dummy Study in Japanese Female Participants to Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

380

Actual

Start

Jan 11, 2023

Primary completion

Feb 2, 2024

Study completion Feb 2, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the consistency of therapeutic response of gepotidacin in female participants with acute uncomplicated cystitis with qualifying bacterial uropathogen(s) at baseline that all are susceptible to nitrofurantoin in Japan, with that from global studies (Studies 204989 \[NCT04020341\] and 212390 \[NCT04187144\]).

Conditions

  • Urinary Tract Infections

Interventions

  • GepotidacinDrug

    Gepotidacin will be administered.

  • NitrofurantoinDrug

    Nitrofurantoin will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Therapeutic Response (TR) (Combined Per-participant Microbiological and Clinical Success) for Gepotidacin at the Test of Cure (TOC) VisitTime frame: At TOC visit (Days 9 to 16)

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Gunma, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Kagoshima, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kochi, Japan

  • GSK Investigational Site

    Miyagi, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Saga, Japan

  • GSK Investigational Site

    Saitama, Japan

  • GSK Investigational Site

    Saitama, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.